title: ω-3 supplementation in HIV-1-infected individuals with unsuppressed viral load: cause for caution?
authors: aGroup of Genomics and Pharmacogenomics, Laboratory of Retrovirology and Viral Immunopathogenesis bGroup of Development of new HIV-1 immunogens, AIDS Research Group, HIVACAT, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona cCIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid dDepartment of Endocrinology and Nutrition, Lipid Clinic eLaboratory of Retrovirology and Viral Immunopathogenesis, Infectious Diseases Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. *Mireia Arnedo and Aleix Sala-Vila have contributed equally to the writing of this article.
authors: Olivia
authors: O
authors: Tort
authors: Sonsoles
authors: S
authors: Sánchez-Palomino
authors: Tuixent
authors: T
authors: Escribà
authors: Carlos
authors: C
authors: Calvo
authors: Tània
authors: T
authors: González
authors: José Maria
authors: JM
authors: Gatell
authors: Aleix
authors: A
authors: Sala-Vila
authors: Mireia
authors: M
authors: Arnedo
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism / Q000821:virology*; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000009:adverse effects; D015658:HIV Infections; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity; D006801:Humans; D008563:Membrane Lipids / Q000032:analysis* / Q000378:metabolism; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D008563:Membrane Lipids; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid